FansUnite to Present at the Virtual Gravitas Titans of Tech Investor Day

FansUnite Entertainment Inc. (CSE: FANS) (OTCQX: FUNFF) ("FansUnite" or the "Company"), a technology company providing leading online gaming solutions, is pleased to announce that it will be participating in the Gravitas Titans of Tech Investor Day taking place Thursday, August 19th, 2021 virtually.

FansUnite's Chief Executive Officer, Scott Burton, and President, Darius Eghdami, are scheduled to present on Thursday, August 19th, 2021 at 11:30 AM PT. Mr. Burton and Mr. Eghdami will also be fielding investor questions during the one-day virtual conference hosted by Gravitas Securities Inc.

"I am looking forward to sharing our vision of becoming a global gaming company with investors at the Gravitas Titans of Tech Investor Day," said Scott Burton, CEO of FansUnite. "With the closing of the recent public offering co-led by Gravitas Securities, the Gravitas Titans of Tech Investor Day is an ideal venue to communicate our progress to investors."

This year's Gravitas Titans of Tech Investor Day will feature several leaders in the growth technology vertical space and will be attended virtually by institutional and retail investors from North America and abroad. For additional details about the conference and Gravitas Securities Inc., please visit: www.gravitassecurities.com.

Conferences Details:

Event: Gravitas Titans of Tech Investor Day (virtual)
Format: Presentation
Date: Thursday, August 19th, 2021
Time: 8:30AM PT - 2:15PM PT
Registration: Link

FansUnite

Per: "Scott Burton" "Darius Eghdami"
Scott Burton Darius Eghdami
Chief Executive Officer President

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high growth potential in new or developing markets.

For further information, please contact:

Prit Singh, Investor Relations at FansUnite
ir@fansunite.com

(905) 510-7636

Scott Burton, Chief Executive Officer of FansUnite
scott@fansunite.com

Darius Eghdami, President of FansUnite
darius@fansunite.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED ‎OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute "forward-‎‎‎looking information" under Canadian securities legislation. Generally, forward-looking information can be ‎‎‎identified by the use of forward-looking terminology such as "believes," "belief," "expects," "intends," ‎‎‎‎"anticipates," "potential," "should," "may," "will," "plans," "continue" or similar expressions to be uncertain ‎‎‎and forward-looking. Forward-looking statements may include, without limitation, statements relating to ‎‎‎future outlook and anticipated events such as; FansUnite's ability to ‎fulfill technology needs with its ‎platform; business development ‎plans of ‎FansUnite; legal framework; the Company's unique portfolio of assets; and discussion of future plans, ‎projections, ‎objectives, estimates ‎and forecasts and the timing related thereto. Forward-looking statements ‎are based ‎on the Company's ‎estimates and are subject to known and unknown risks, uncertainties and ‎other factors ‎that may cause the ‎actual results, level of activity, performance or achievements of ‎FansUnite to be ‎materially different from ‎those expressed or implied by such forward-looking statements or ‎forward-looking ‎information. Additional ‎information regarding the risks and uncertainties relating to the ‎Company's business ‎are contained under ‎the heading "Risk Factors" in the Company's Non-Offering ‎Prospectus dated March 27, ‎‎2020 filed on its ‎issuer profile on SEDAR at www.sedar.com and risks related ‎to global pandemics, ‎including the novel ‎coronavirus (COVID-19) global health pandemic, and the spread of ‎other viruses or ‎pathogens and influence ‎of macroeconomic developments. Accordingly, readers should not ‎place undue ‎reliance on forward-looking ‎statements and forward-looking information. The forward-looking ‎statements in ‎this news release are made ‎as of the date of this release. FansUnite disclaims and does not ‎undertake to ‎update or revise any forward-‎looking statements or forward-looking information, whether as a ‎result of new ‎information, future events or ‎otherwise, except as required by applicable.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/93230

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
E-Power Resources Inc. Announces Commencement of the 2024 Tetepisca Exploration Program

E-Power Resources Inc. Announces Commencement of the 2024 Tetepisca Exploration Program

Commencement of the Tetepisca Exploration Program for 2024

E-Power Resources Inc. (CSE: EPR) ("E-Power" or the "Company") announces that it has mobilized its exploration crew to the Tetepisca Graphite Project and the 2024 exploration program is underway.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Apple The Exchange TRX to welcome its first customers this Saturday, June 22, in Kuala Lumpur

Apple The Exchange TRX to welcome its first customers this Saturday, June 22, in Kuala Lumpur

Apple's first retail location in Malaysia will offer its full lineup of products and services, unparalleled support from over 160 team members, and sessions with local creatives

Apple® today previewed Apple The Exchange TRX, the first Apple Store® in Malaysia. Located in the heart of Kuala Lumpur's new Tun Razak Exchange (TRX) central business district, the new store will deliver the magic of Apple in the country like never before. Customers can discover and buy Apple's innovative lineup of products and services, receive exceptional service from knowledgeable team members, and learn how to get the most out of their devices through free Today at Apple® sessions.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
XReality Group

Additional Working Capital Secured

xReality Group Limited (“XRG” or the “Company”) is pleased to announce that it has secured an additional $500,000 in working capital through its senior debt holder, Causeway Financial. The additional working capital will be utilised to provide inventory for the increasing demand in the United States markets.

Keep reading...Show less

Latest Press Releases

Related News

×